Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion

Hepatology. 2004 Mar;39(3):688-98. doi: 10.1002/hep.20089.

Abstract

The present study evaluates the effect of ischemic preconditioning on interleukin-1 (IL-1) and interleukin-10 (IL-10) generation following hepatic ischemia/reperfusion (I/R) in normal and steatotic livers as well as the role of nitric oxide (NO) in this process. Increased IL-1beta and IL-10 levels were observed in normal livers after I/R. Steatotic livers showed higher IL-1beta levels than normal livers, and IL-10 at control levels. The injurious role of IL-1beta and the benefits of IL-10 on hepatic I/R injury was shown with the use of IL-1 receptor antagonist (IL-1ra), anti-IL-10 polyclonal antibody against IL-10 (anti-IL-10) and exogenous IL-10. The effective dose of these treatments was different in both types of livers. Preconditioning prevented IL-1beta release and increased IL-10 generation after I/R in normal and steatotic livers. IL-1beta or anti-IL-10 pretreatments reversed the benefits of preconditioning. IL-1beta action inhibition in a preconditioned group that was pretreated with anti-IL-10 did not modify the benefits of preconditioning. In addition, anti-IL-10 pretreatment in the preconditioned group resulted in IL-1beta levels comparable to those observed after I/R. NO inhibition eliminated the benefits of preconditioning on IL-10 release, IL-1beta levels, and hepatic injury. In conclusion, preconditioning, through IL-10 overproduction, inhibits IL-1beta release and the ensuing hepatic I/R injury in normal and steatotic livers. IL-10 generation induced by preconditioning could be mediated by NO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / administration & dosage
  • Antibodies / pharmacology
  • Dose-Response Relationship, Drug
  • Fatty Liver / complications
  • Fatty Liver / metabolism*
  • Fatty Liver / pathology
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1 / antagonists & inhibitors
  • Interleukin-1 / metabolism*
  • Interleukin-10 / immunology
  • Interleukin-10 / metabolism
  • Interleukin-10 / pharmacology
  • Ischemic Preconditioning*
  • Liver Circulation*
  • Nitric Oxide / antagonists & inhibitors
  • Rats
  • Rats, Zucker
  • Reperfusion Injury / complications
  • Reperfusion Injury / metabolism*
  • Reperfusion Injury / pathology
  • Sialoglycoproteins / administration & dosage
  • Sialoglycoproteins / pharmacology

Substances

  • Antibodies
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1
  • Sialoglycoproteins
  • Interleukin-10
  • Nitric Oxide